Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Cash and Equivalents of $14.44 million for fiscal year 2025.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.44M | +7.1% |
| 2024 | $13.48M | -42.3% |
| 2023 | $23.37M | +26.2% |
| 2022 | $18.52M | -37.6% |
| 2021 | $29.69M | +238.9% |
| 2020 | $8.76M | +12545.7% |
| 2020 | $69.3K | +35794.3% |
| 2019 | $193.00 | -99.9% |
| 2019 | $313.0K | — |
| 2018 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.18M | +137.2% | +27.2% |
| June 30, 2025 | $10.36M | +67.7% | +95.9% |
| March 31, 2025 | $5.29M | -55.8% | -60.8% |
| December 31, 2024 | $13.48M | -42.3% | +142.4% |
| September 30, 2024 | $5.56M | +11.8% | -10.0% |
| June 30, 2024 | $6.18M | -44.6% | -48.4% |
| March 31, 2024 | $11.97M | +6.4% | -48.8% |
| December 31, 2023 | $23.37M | +26.2% | +370.0% |
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +7.1% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from REVIVA PHARMACEUTICALS HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: